Lexicon Pharmaceuticals Provides Regulatory Update on Sotagliflozin in Heart Failure

The Woodlands, Texas, January 14, 2021 – Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it has received U.S. Food and Drug Administration (FDA) regulatory feedback that the results of its SOLOIST and SCORED Phase 3...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials